Team Category: Board of Directors

Carlos Gonzalez

Carlos Gonzalez founded Rivas Capital in 2007 and serves as its CEO.

Rivas is a privately held firm focused on long-term principal investments across multiple asset classes.  Rivas holds controlling interests in a range of Latin American food businesses and manages a portfolio of investments in early-stage agtech and biotech startups. Carlos serves on the boards of ReviveMed, Aircuity, and Lumicell (as observer).   He holds an AB in Economics from Harvard College and an MBA from Harvard Business School.

Jingwen Wang

Jingwen Wang is a Portfolio Manager at Verition Fund Management, a global multi-strategy hedge fund, where she manages healthcare investments in both public and private markets across US, Europe, and Asia.

Jingwen has 20 years of experience in the healthcare industry across public and private investing, management consulting, technology transfer and translational research. Prior to Verition, she worked as a healthcare investment analyst at Balyasny Asset Management, Surveyor Capital (part of Citadel), and started her career as a management consultant in McKinsey’s healthcare practice in New York. While a graduate student, she was a Fellow at the technology transfer office, Columbia Technology Ventures. She received her PhD with distinction in Biological Sciences with a focus on neuroscience from Columbia University, and her BS in Biological Sciences from Beijing University.

Andrey J. Zarur, Ph.D

Andrey co-founded GreenLight Biosciences in 2008 to develop advanced biological solutions to overcome some of the biggest challenges faced by the human race, including sustainable food production, response and preparedness for pandemics, and global access to effective human health.

He is a co-founder and was Chairman of the Board of Solid Biosciences, Inc. (NASDAQ: SLDB), a gene-therapy company targeting Duchenne Muscular Dystrophy. He is also co-founder and Chairman of the Board at Lumicell Surgical, an oncology company delivering advanced imaging solutions to cancer surgery. He has been a co-founder and senior executive in more than a dozen companies in the healthcare and clean energy sectors. Prior to starting GreenLight, Andrey was Managing Partner at Kodiak Venture Partners, an early-stage, technology-driven venture fund based in Boston.

Dr. Zarur carried out graduate doctoral studies in Chemical and Biomedical Engineering at the Massachusetts Institute of Technology, and Immunology at Harvard-MIT. Andrey is a frequent invited speaker at scientific and trade conferences, has authored a number of landmark peer-reviewed articles in prestigious scientific journals, holds over 100 provisional and issued patents and has been regularly quoted in international media on the pandemic and RNA vaccines, including recent opinion pieces in Fortune and Stat as well as quotes in the Financial Times, Investors Business Daily, Wired, Business Insider  and CNBC.

Eric O’Brien

Eric O’Brien is Co-Founder and Managing Director of Fall Line Capital, bringing over 18 years of professional investment, financial services and operating experience to the firm.

Prior to forming Fall Line with Clay Mitchell in 2011, Eric spent 12 years at Lightspeed Venture Partners, a top tier Silicon Valley venture capital firm with over $3 billion of assets under management. At Lightspeed, he was a Managing Director responsible for early and growth stage investments in technology and services companies in the U.S. and China.

Eric has a track record of identifying and executing effectively against emerging market opportunities. In 2004, he identified a strategic opportunity for Lightspeed to expand its activities to China, where very few U.S. venture capital firms had established themselves at the time. That year, he sourced the firm’s first investment in the region and led the creation of Lightspeed’s overall strategy for China. In 2006, he moved himself and his family to Shanghai for five months to help formally establish Lightspeed’s China office, build the local investment team, and make several of the firm’s initial investments in the region, one of which became the firm’s first successful liquidity event in China.

Prior to Lightspeed, Eric was an Associate at InterWest Partners, a Silicon Valley venture capital firm where he focused on communications, internet and consumer investments. He has also worked for and consulted to a number of technology startups, and started his career as an Analyst in the mergers and acquisitions and corporate finance groups at Morgan Stanley in New York and San Francisco. Eric holds an AB degree in Economics magna cum laude from Harvard College and an MBA from the Stanford Graduate School of Business.

Matthew Walker

Matthew Walker is a Managing Director at S2G Ventures.

His efforts are focused on sourcing and evaluating potential investment opportunities, and contributing to the business development efforts of portfolio companies. Before joining S2G Ventures, Matt was an investment banking Associate at Perella Weinberg Partners in New York focused on M&A and restructuring transactions across a range of industries. Prior to that role, he was a securities attorney in the Funds, Regulation, and Equity Derivatives practice at Cadwalader, Wickersham & Taft, LLP in New York. Matt has an MBA from The University of Chicago Booth School of Business, a J.D. from New York University School of Law, and a B.S. in Mechanical Engineering from the University of Michigan.